Delivery Order SPE2DB22D1103-SPE2DB25FTSP8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,244.42 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units). The contract, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The U.S. Defense Logistics Agency (DLA) awarded a $10,153.73 firm-fixed price delivery order to AmerisourceBergen Drug Corporation's Corporate Office division. The order is for the supply of 4,566,078,136 units of the pharmaceutical product CAPLYTA 42 MG CAPSULE 30S. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 with DLA Troop Support Medical, which provides a wide range of medical commodities to support military treatment programs and...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at $5,153.50 to Amerisourcebergen Drug Corporation. Under the contract, Amerisourcebergen will provide 4561454927 capsules of CAPLYTA, a 21mg antipsychotic medication, for delivery to a facility located in Conshohocken, Pennsylvania. The single delivery is to be completed by July 11, 2023. As a major supplier of pharmaceuticals and medical supplies to the U.S. Department of Defense, this order for CAPLYTA capsules...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide CAPLYTA 42 MG CAPSULE 30S. The $4,177.44 delivery order was issued under a larger indefinite delivery contract and is set to be completed by December 26, 2023. Amerisourcebergen Drug Corp, as a prime contractor, has a history of supplying pharmaceuticals, medical supplies, and related distribution services to DLA Troop Support...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract valued at $13,672.67. The delivery order, which serves as a child contract to a larger vehicle, is set to be completed by July 28, 2025. This award was competitively procured with no set-aside designation and reflects AmerisourceBergen's role as a critical pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a $9,458.27 firm fixed price delivery order contract to AmerisourceBergen Drug Corp for the supply of Caplyta 42 mg capsules. The contract has an ultimate completion date of August 2, 2024 and does not utilize a set-aside. AmerisourceBergen, a major pharmaceutical distributor, provides a wide range of prescription medications, medical supplies, and equipment to federal agencies through various indefinite delivery contracts. This delivery order is part...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide CAPLYTA 42 MG CAPSULE 30S pharmaceuticals. This $3,279.97 delivery order was awarded on December 22, 2023 with a completion date of December 26, 2023. Amerisourcebergen Drug Corp is a prime contractor that has received numerous federal contract awards from DLA to supply pharmaceuticals, medical supplies, and...
- This is a delivery order federal contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of CAPLYTA 42 MG CAPSULE 30S, a pharmaceutical product, with a ceiling value of $11,109.74 and a period of performance through July 7, 2025. The contract is a firm-fixed-price, non-set-aside award, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,815.69 contract is for the supply of 4568568707, CAPLYTA 42 MG CAPSULE 30S, with a completion date of June 17, 2025. The award is not set-aside and was made on June 16, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CAPLYTA 42 MG CAPSULE 30S, a pharmaceutical product, with a ceiling value of $15,025.07. The contract is a firm fixed-price delivery order and is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FTSP8Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract valued at $10,226.69. The award was made on July 24, 2025, with an ultimate completion date of July 25, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its Pennsylvania facility. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle provides comprehensive pharmaceutical support globally and enables the company to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs. CAPLYTA is a psychiatric medication used in the treatment of schizophrenia and bipolar disorder, reflecting the Defense Health Agency's procurement of specialty pharmaceuticals for military healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.2k | 7/24/25 |